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Abstract
Introduction: Sebaceous gland tumours are rare and their presence should be considered as a
marker for Muir-Torre Syndrome, alerting to search for an occult malignancy.
Case presentation: A 43-year-old Caucasian female patient underwent excision of a sebaceous
cyst. Histopathology confirmed a sebaceous carcinoma. Further investigations revealed multiple
intra-abdominal malignancies. She has been under regular follow-up in the relevant clinics.
Conclusion:  Sebaceous carcinoma should be excised completely and followed-up for the
detection of possible metastases. Surgical removal of primary or metastatic cancers may be curative
and should be attempted wherever possible. It is very important for clinicians not to miss such skin
lesions as they may precede the presentation of internal malignancies.
Introduction
Muir-Torre Syndrome (MTS) is defined by the combina-
tion of a sebaceous gland tumour and at least one visceral
carcinoma occurring in the same individual in the absence
of other precipitating factors such as radiotherapy or
AIDS. Typical skin lesions associated with this syndrome
include sebaceous adenoma, epithelioma and carcinoma.
Case presentation
A 43-year-old Caucasian woman had an excision of an
infected sebaceous cyst from the skin of her left breast in
2007. Histopathology reported an incompletely excised
sebaceous carcinoma, suggestive of MTS. The patient was
referred to the breast clinic for further assessment. She had
an extensive family history of cancers. Her father died of
prostate cancer, her mother had a hysterectomy for uter-
ine cancer, her maternal grandmother had uterine cancer,
her sister had bowel cancer and her great paternal aunt
had breast cancer. Clinical examination revealed a scar in
the lower half of her left breast and two sebaceous cysts
over her left nipple and left upper arm. She was also ten-
der in the right iliac fossa and was investigated by a gynae-
cologist. Her chest X-ray and bilateral mammogram were
normal. The patient underwent wider excision of the left
breast scar and of skin lesions over the left nipple and the
left upper arm. Histology reported no residual neoplasia
in the excised scar and the skin lesions were benign epi-
dermoid cysts.
A computed tomography (CT) scan of the chest, abdomen
and pelvis showed bilateral ovarian cysts and diverticular
disease of the colon. The tumour markers were raised:
CA125: 149 (0–35); CA19-9: 61.8 (0–35). She later
underwent total abdominal hysterectomy, bilateral salp-
ingo-oophorectomy and infracolic partial omentectomy.
The histology was Stage IC moderately differentiated
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endometrioid adenocarcinoma of the right ovary, Stage IC
endometrioid endometrial adenocarcinoma, and the
omentum was normal. She was referred to a geneticist,
oncologist, gastroenterologist and dermatologist. The
genetic analysis showed (MSH2s.1578DEL). She had a
gastroscopy which showed duodenitis and a colonoscopy
which was normal. She had chemotherapy followed by
radiotherapy.
Discussion
Cutaneous lesions associated with hereditary cancer syn-
dromes are known as cancer-associated genodermatoses
[1]. One of these is MTS, defined by the combination of a
sebaceous gland tumour and at least one visceral carci-
noma occurring in the same individual in the absence of
other precipitating factors such as radiotherapy or AIDS
[2]. It was first described by Muir in 1967 and Torre in
1968, and is recognized as a subtype of Lynch Type II
Hereditary Nonpolyposis Colon Cancer (HNPCC) [3,4].
A review by Akhtar et al. (1999) identified a total of 205
reported cases in the world literature [5]. The male/female
ratio is 3:2 [6]. It is an autosomal dominant disorder with
a high degree of penetrance and variable expression and
the children of an affected individual have a 50% risk of
inheriting the cancer predisposition. The genetic disorder
is an inherited germline mutation in one of the DNA mis-
match repair (MMR) genes, most commonly MSH2,
which eventually leads to microsatellite instability (MSI)
[7].
Typical skin lesions associated with this syndrome include
sebaceous adenoma, epithelioma and carcinoma (seba-
ceous hyperplasia and nevus sebaceous of Jadassohn are
generally excluded). Keratoacanthomas and basal cell car-
cinomas with sebaceous differentiation can also occur.
Sebaceous gland tumours are rare and their presence
should be considered as a marker for MTS, alerting to
search for an occult malignancy [8]. Skin lesions may pre-
cede the presentation of internal malignancies, but often
develop later. Fifty-six percent of skin lesions occur after
the diagnosis of the first malignancy, 6% occur concomi-
tantly and 22% occur as the first malignancy of the syn-
drome [5]. The cutaneous lesion may occur as much as 25
years before or 37 years after the internal malignancy.
Multiple primary carcinomas at different sites are charac-
teristic of MTS (Table 1), and up to nine visceral cancers
have been reported in one individual [9].
Colorectal cancer is the commonest visceral neoplasm to
occur in MTS, and the most frequent initial cancer
[10,11], though not in our case. In common with other
forms of HNPCC, colorectal cancers in MTS are usually
proximal in location and tend to have a more indolent
course than usual colorectal cancers [11]. Fifty-one per-
cent of MTS patients develop at least one colorectal can-
cer, and multiple colorectal cancers are common [12].
Colonic polyps are found in more than 25% of MTS
patients, and are especially prevalent in patients with
colorectal carcinoma [12].
The second most common site is the genitourinary tract
(including endometrium and ovary), representing
approximately one-quarter of visceral cancers. A wide vari-
ety of other cancers have been reported involving breast,
upper gastrointestinal tract, upper respiratory tract includ-
ing larynx, salivary gland, and haematological malignan-
cies including lymphoma and leukaemia. Intestinal
polyps occur in at least one-quarter of patients [12].
In families with proven germline mutation, individuals
should be offered regular screening examinations. In
those who can be demonstrated not to have inherited the
germline mutation, cancer surveillance is not necessary
[13]. Screening for malignancy at all possible sites is
impractical in MTS given the wide range of associated
malignancies, and should probably concentrate on the
colorectum, female genital tract and possibly the renal
tract. In some families, the occurrence of certain other
tumours would be an indication for other screening
modalities, for example, upper gastrointestinal endoscopy
[14]. Cohen et al. [11] suggested that a search for internal
malignancies should be undertaken in those with MTS-
associated sebaceous gland tumour, those with MTS, and
in family members of an MTS patient. They also suggested
a surveillance programme for patients with MTS or MTS-
associated sebaceous gland tumours including annual
clinical examination, carcinoembryonic antigen (CEA),
cervical smear, chest radiography, urine cytology, colon-
oscopy or barium enema every 3 to 5 years, and for female
patients, mammography annually or biennially to age 50
and annually thereafter, and endometrial biopsy every 3
to 5 years. Other authors have suggested that colonoscopy
should be more frequent in view of the high frequency of
colonic cancer and its proximal predominance, and have
advocated annual colonoscopy from the age of 25 years
[10]. MTS screening may be extensive and is not always
performed. A search for mutations in either MSH1 or
Table 1: Prevalence of cancers associated with MTS
Cancer Percentage (%)
Colorectal 80
Stomach 11–19
Hepatobiliary tract 2–7
Small intestine 1–4
Brain or central nervous system 1–3
Endometrial 20–60
Ovarian 9–12
Urinary tract 4–5
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MSH2 is expensive and time consuming. One could ana-
lyse MMR protein expression as a surrogate for assaying
for the respective gene mutations [15]. Benign sebaceous
tumours and keratoacanthomas can be conservatively
treated with excision or cryotherapy. Sebaceous carci-
noma should be excised completely and followed-up for
the detection of possible metastases. It has been suggested
that, because of their relatively good prognosis and non-
aggressive course, surgical removal of primary or meta-
static cancers may be curative and should be attempted
wherever possible [5,7]. The combination of interferon
with retinoids (isotretinoin) seems to be of promise in
preventing tumour development in MTS. A dosage of 0.8
mg/kg/day may be effective [10].
Conclusion
Sebaceous gland tumours are rare and their diagnoses
should suggest the possibility of MTS and prompt a search
for associated malignancies, and for the underlying
genetic mutation. Family members should be offered
screening to detect early cancers. Genetic studies can help
identify the inherited molecular defect that causes MTS.
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